Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
Statistical Approaches For Studying The Safety And Effectiveness Of Medicines
Funder
National Health and Medical Research Council
Funding Amount
$307,946.00
Summary
When medicines first reach the market many of the potential adverse reactions are unknown. Clinical trials of medicines often exclude elderly patients and patients with multiple chronic diseases who are at higher risk of adverse drug reactions. This research aims to improve medicine safety by developing statistical methods to detect and validate medication safety signals and to identify patients who are at high risk of adverse reactions to medicines.
Predicting Drug-drug Interactions Due To Tyrosine Kinase Inhibitors: Inhibition Of Drug Metabolising Enzymes And Transporters
Funder
National Health and Medical Research Council
Funding Amount
$535,495.00
Summary
Tyrosine kinase inhibitors (TKIs) are a new class of anticancer agents. Cancer patients typically receive multiple drugs, for the treatment of cancer and other diseases, increasing the probability of interactions between coadministered drugs. Despite the widespread use of TKIs, their potential to cause drug interactions is poorly understood. Using novel in vitro approaches, this project will identify drug interactions precipitated by TKIs thereby improving drug efficacy and patient safety.
Lipoceramic Technologies: A Solution To Low And Variable Bioavailability Of Poorly Soluble Anti-inflammatory Drugs
Funder
National Health and Medical Research Council
Funding Amount
$200,600.00
Summary
A novel oral drug delivery platform will be developed that improves the absorption of poorly soluble drugs from the GI tract, leads to improved clinical outcomes and has significant commercial value. This development will be based on the combination of formulation, in vitro analysis and in vivo animal model studies. An advanced prototype formulation will be established for celecoxib (a non-steroidal anti-inflamatory drug) that will be suitable for human phase 1 clinical trials.
The Alfred/Monash Centre For Therapeutics And Clinical Research
Funder
National Health and Medical Research Council
Funding Amount
$2,000,000.00
Summary
The Centre will provide a national resource for the evaluation of new and existing drugs. It will focus particularly on investigator-initiated research that is not well served by present funding arrangements. With the cost of pharmaceuticals rising at an annual rate of 15-20 percent there is a clear need for independently developed, comparative information on both new and existing agents. It will also address the virtual absence in Australia of a major academic research focus on drug safety and ....The Centre will provide a national resource for the evaluation of new and existing drugs. It will focus particularly on investigator-initiated research that is not well served by present funding arrangements. With the cost of pharmaceuticals rising at an annual rate of 15-20 percent there is a clear need for independently developed, comparative information on both new and existing agents. It will also address the virtual absence in Australia of a major academic research focus on drug safety and pharmacoeconomics.Read moreRead less
In Vivo Evaluation Of The Safety And Efficacy Of A Novel Chitosan Gel In The Reduction Of Adhesions Following Abdominal Surgery In Both Animal And Human Models
Funder
National Health and Medical Research Council
Funding Amount
$532,076.00
Summary
Up to 95% of abdominal surgery patients will develop adhesions within the abdomen, with nearly 1 in 5 requiring hospital readmission for pain, reduced gastrointestinal function and bowel obstruction. Newly developed Chitodex gel has been shown to be effective in the control of bleeding and the reduction of adhesions following sinus surgery. These projects will now explore its use in abdominal surgery. Chitodex gel has the potential to benefit millions of patients each year and drastically lessen ....Up to 95% of abdominal surgery patients will develop adhesions within the abdomen, with nearly 1 in 5 requiring hospital readmission for pain, reduced gastrointestinal function and bowel obstruction. Newly developed Chitodex gel has been shown to be effective in the control of bleeding and the reduction of adhesions following sinus surgery. These projects will now explore its use in abdominal surgery. Chitodex gel has the potential to benefit millions of patients each year and drastically lessen the burden on our health system.Read moreRead less
Evaluation Of The Safety Of Lead Compounds For Allergic Asthma
Funder
National Health and Medical Research Council
Funding Amount
$310,568.00
Summary
Asthma is one of the most common chronic respiratory diseases in developed countries and is typically treated with corticosteroids which provide symptomatic relief and coarse non-specific treatment of the underlying disease. We are pursuing innovative therapies by targeting a different enzyme, HPGD2S, involved in the inflammatory mechanisms of asthma. We have developed potent, anti-inflammatory drug candidates and aim to profile the safety of these compounds before entering clinical studies.
Population-level Vaccine Safety Monitoring: Risk Assessment And Policy Implications
Funder
National Health and Medical Research Council
Funding Amount
$85,649.00
Summary
Vaccines prevent millions of deaths worldwide but events can occur after vaccination which may or may not be related to the vaccine. It is vital to ensure vaccines are safe and that both the public and medical providers remain confident in vaccination programs. The PhD thesis will look at the various methods for monitoring vaccine safety in Australia, and compare the usefulness of each system. This will provide information for policy makers on the safety of vaccines in Australia.
Therapeutic Treatment Pathways And Their Impact On Medicine Safety And Effectiveness
Funder
National Health and Medical Research Council
Funding Amount
$336,070.00
Summary
In clinical trials medicines are assumed to be used regularly with a set dose over the duration of the study. However, in real life medicines are used in different doses, over different durations and together with other medicines, which affect the effectiveness and safety of the treatment. The aim of this proposed research is to evaluate how different treatment pathways impact medicine safety and effectiveness. This project will provide new information on safety and effectiveness of treatment pa ....In clinical trials medicines are assumed to be used regularly with a set dose over the duration of the study. However, in real life medicines are used in different doses, over different durations and together with other medicines, which affect the effectiveness and safety of the treatment. The aim of this proposed research is to evaluate how different treatment pathways impact medicine safety and effectiveness. This project will provide new information on safety and effectiveness of treatment pathways.Read moreRead less
A Novel Nitric Oxide-based Treatment For Recalcitrant Staphylococcus Aureus-associated Chronic Rhinosinusitis
Funder
National Health and Medical Research Council
Funding Amount
$541,377.00
Summary
Chronic rhinosinusitis (CRS) is a common condition affecting the lives of up to 16% of the population. With yet no cure, the search for effective means of therapy is crucial. Patients with severe disease are most often found to have infection with the bacteria Staphylococcus aureus, associated with more severe symptoms and reduced quality of life. This study will investigate the effectiveness of a novel topical liposome-encapsulated nitric oxide in the treatment of this burdensome disease.